Breaking News, Collaborations & Alliances

Codexis & KYORIN Enter Supply Agreement

For the supply of a proprietary enzyme to be used in the manufacture of vibegron to treat overactive bladder

Codexis has announced a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova Tablets, a novel, once-daily treatment for overactive bladder. The product was commercially launched in Japan in November 2018. “Our CodeEvolver technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters